Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IXHL Incannex Healthcare	$0.22 +10.0%	$0.27	$0.08 ▼ $3.39	$5.89M	7.64	14.26 million shs	22.63 million shs
JAGX Jaguar Animal Health	$3.05 +13.0%	$6.07	$2.61 ▼ $110.75	$2.75M	0.68	52,265 shs	107,514 shs
NERV Minerva Neurosciences	$1.82 +2.6%	$1.66	$1.15 ▼ $3.50	$12.38M	-0.37	23,172 shs	3,172 shs
SPRB Spruce Biosciences	$0.07 +0.1%	$0.08	$0.06 ▼ $0.61	$2.96M	2.38	700,111 shs	235,522 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IXHL Incannex Healthcare	+10.00%	+0.18%	+1.06%	-69.49%	-93.49%
JAGX Jaguar Animal Health	+12.96%	-5.57%	-32.07%	-40.55%	-96.78%
NERV Minerva Neurosciences	+2.60%	-1.30%	+24.38%	-2.63%	-44.12%
SPRB Spruce Biosciences	+0.14%	-3.58%	+11.27%	-78.03%	-87.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IXHL Incannex Healthcare	0.2204 of 5 stars	0.0	4.0	0.0	0.0	0.8	0.0
JAGX Jaguar Animal Health	2.1267 of 5 stars	3.5	5.0	0.0	0.0	0.0	0.6
NERV Minerva Neurosciences	3.5135 of 5 stars	3.0	3.0	4.6	0.0	0.0	1.3
SPRB Spruce Biosciences	2.0898 of 5 stars	3.0	3.0	0.0	0.6	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A
JAGX Jaguar Animal Health	3.00	Buy	$60.00	1,867.21% Upside
NERV Minerva Neurosciences	2.00	Hold	$5.00	175.33% Upside
SPRB Spruce Biosciences	2.00	Hold	$1.75	2,396.43% Upside

Current Analyst Ratings Breakdown

Latest JAGX, IXHL, SPRB, and NERV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/19/2025	JAGX Jaguar Animal Health	First Berlin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
4/16/2025	SPRB Spruce Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$1.50 ➝ $0.50

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IXHL Incannex Healthcare	$98K	66.08	N/A	N/A	$0.18 per share	1.22
JAGX Jaguar Animal Health	$11.69M	0.27	N/A	N/A	$12.29 per share	0.25
NERV Minerva Neurosciences	N/A	N/A	$0.21 per share	8.47	($3.67) per share	N/A
SPRB Spruce Biosciences	$4.91M	0.60	N/A	N/A	$1.88 per share	0.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-342.92%	-148.64%	N/A
JAGX Jaguar Animal Health	-$38.49M	N/A	0.00	N/A	N/A	-343.92%	-432.91%	-71.25%	8/12/2025 (Estimated)
NERV Minerva Neurosciences	$1.44M	$0.82	2.21	N/A	N/A	N/A	-20.68%	15.73%	8/5/2025 (Estimated)
SPRB Spruce Biosciences	-$47.92M	-$1.32	N/A	N/A	N/A	-555.23%	-62.10%	-47.49%	8/11/2025 (Estimated)

Latest JAGX, IXHL, SPRB, and NERV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q3 2025	IXHL Incannex Healthcare	-$0.46	-$0.24	+$0.22	-$0.20	$0.16 million	$0.10 million
5/15/2025	Q1 2025	JAGX Jaguar Animal Health	-$18.50	-$16.70	+$1.80	-$16.70	$3.29 million	$3.50 million
5/13/2025	Q1 2025	NERV Minerva Neurosciences	-$1.07	-$0.50	+$0.57	-$0.50	N/A	N/A
4/15/2025	Q4 2024	SPRB Spruce Biosciences	-$0.20	-$0.57	-$0.37	-$0.57	$0.50 million	$0.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
JAGX Jaguar Animal Health	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IXHL Incannex Healthcare	N/A	2.12	2.12
JAGX Jaguar Animal Health	22.20	1.08	0.70
NERV Minerva Neurosciences	N/A	9.21	9.21
SPRB Spruce Biosciences	0.01	5.36	5.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IXHL Incannex Healthcare	0.43%
JAGX Jaguar Animal Health	12.04%
NERV Minerva Neurosciences	34.56%
SPRB Spruce Biosciences	91.71%

Insider Ownership

Company	Insider Ownership
IXHL Incannex Healthcare	15.49%
JAGX Jaguar Animal Health	0.38%
NERV Minerva Neurosciences	8.60%
SPRB Spruce Biosciences	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IXHL Incannex Healthcare	3	29.43 million	24.88 million	Not Optionable
JAGX Jaguar Animal Health	50	1.02 million	1.01 million	No Data
NERV Minerva Neurosciences	9	6.99 million	6.39 million	Not Optionable
SPRB Spruce Biosciences	20	42.23 million	37.54 million	Optionable

JAGX, IXHL, SPRB, and NERV Headlines

Recent News About These Companies

SPRB Spruce Biosciences, Inc. - Seeking Alpha

June 24 at 10:41 PM | seekingalpha.com

Spruce Biosciences gets conditional approval to resume trading on Nasdaq Capital Market

June 13, 2025 | msn.com

Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market

June 12, 2025 | finance.yahoo.com

Spruce Biosciences’ Compliance Plan Accepted by Nasdaq

June 12, 2025 | tipranks.com

Spruce Biosciences’ SWOT analysis: stock pivots amid clinical setbacks

May 7, 2025 | investing.com

Spruce Biosciences Inc Ordinary Shares

May 6, 2025 | morningstar.com

Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 6, 2025 | finance.yahoo.com

Spruce Axes 55% of Staff, Leaving Shoestring Crew To Focus on New Rare Disease Asset

April 28, 2025 | biospace.com

Spruce halves head count, narrowing focus to get ex-BioMarin drug to FDA

April 28, 2025 | fiercebiotech.com

Spruce Biosciences (SPRB) Receives a Hold from RBC Capital

April 17, 2025 | markets.businessinsider.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call Transcript

April 17, 2025 | insidermonkey.com

Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

April 15, 2025 | standard-journal.com

With BioMarin deal, Spruce Biosciences hits reset on rare-disease drug

April 15, 2025 | bizjournals.com

Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)

April 15, 2025 | seekingalpha.com

Spruce Biosciences reports delayed annual filing

April 3, 2025 | investing.com

Spruce Biosciences Inc (SPRB) Stock: Understanding Its Underlying Value

February 5, 2025 | bovnews.com

Hold Rating for Spruce Biosciences Amid Clinical Setbacks and Strategic Uncertainties

December 16, 2024 | markets.businessinsider.com

Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why

December 13, 2024 | zacks.com

JMP Securities Downgrades Spruce Biosciences (SPRB)

December 12, 2024 | msn.com

Spruce saws off only drug after 2nd hyperplasia fail, leaving biotech's direction in doubt

December 11, 2024 | fiercebiotech.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAGX, IXHL, SPRB, and NERV Company Descriptions

Incannex Healthcare NASDAQ:IXHL

$0.22 +0.02 (+10.00%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$0.21 -0.01 (-2.73%)

As of 07:56 AM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Jaguar Animal Health NASDAQ:JAGX

$3.05 +0.35 (+12.96%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$3.06 +0.01 (+0.33%)

As of 07:55 AM Eastern

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Minerva Neurosciences NASDAQ:NERV

$1.82 +0.05 (+2.60%)

Closing price 06/24/2025 03:58 PM Eastern

Extended Trading

$1.82 +0.00 (+0.22%)

As of 06/24/2025 04:04 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Spruce Biosciences NASDAQ:SPRB

$0.07 +0.00 (+0.14%)

As of 06/24/2025 03:26 PM Eastern

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time